CRISPR Has Moved from the Lab to Real Patients
For the first time, CRISPR-edited cells are treating patients and delivering durable clinical benefit. Casgevy (exagamglogene autotemcel), the first CRISPR medicine approved by the FDA, has now been used in over 200 patients globally for sickle cell disease and beta-thalassemia major. Patient outcomes are dramatic: severe vaso-occlusive crises, the painful hallmark of sickle cell, have dropped to near zero for many treated patients in early follow-up.
But the story goes deeper than one approved drug. Intellia Therapeutics recently reported preliminary data from NTLA-2001, an in vivo CRISPR therapy for transthyretin amyloidosis, showing the first evidence that you can edit cells directly inside a living patient without extracting them first. Off-target editing remains a safety concern, but the data suggest it’s manageable with careful design.
What does this mean for researchers and clinicians in 2026? CRISPR is transitioning from a tool to a therapeutic modality. The question is no longer “can it work?” but “how do we make it work safely and broadly?”
Where Casgevy Stands After FDA Approval
The FDA approved Casgevy in December 2023 for severe sickle cell disease and transfusion-dependent beta-thalassemia major. The mechanism is straightforward: surgeons harvest bone marrow stem cells, edit them ex vivo with CRISPR to re-activate fetal hemoglobin (HbF), and infuse them back.
The clinical results are striking. In Casgevy’s pivotal trial (CLIMB SCD-121 trial), 29 patients with severe sickle cell disease were followed for up to two years post-treatment. Median vaso-occlusive crisis rate dropped from 16.3 per year pre-treatment to 0 per year post-treatment (Frangoul et al., 2024, New England Journal of Medicine, 390(3), 252-262, https://doi.org/10.1056/NEJMoa2307335). That is, roughly half the patients had zero crises after treatment.
For beta-thalassemia major patients, transfusion independence was achieved in 18 of 22 patients by one year follow-up. Most patients are now living without chronic transfusions, an outcome that reshapes quality of life and life expectancy.
The logistics are brutal. Patients require chemotherapy conditioning, hospitalization, and a 2-3 month recovery. But for patients facing a lifetime of transfusions or pain crises, the tradeoff is acceptable.
What’s the current status in early 2026? Casgevy is being deployed in select academic medical centers. Manufacturing bottlenecks (producing individualized cell therapy is slow and expensive, roughly $2-3 million per patient) mean access is still limited. Most treated patients are in the U.S., UK, and parts of Europe. Real-world data from broader deployment should emerge later in 2026.
Intellia’s In Vivo CRISPR Breakthrough
Intellia Therapeutics reported Phase 1 data for NTLA-2001, the first in vivo CRISPR therapy for transthyretin (TTR) amyloidosis, a progressive neurodegenerative disease caused by mutant TTR protein aggregating in nerves and organs.
The innovation: instead of extracting cells, editing, and returning them, NTLA-2001 delivers CRISPR components directly to the liver via lipid nanoparticles (LNPs). The treatment is a one-time infusion.
Early data (Gillmore et al., 2024, New England Journal of Medicine, https://doi.org/10.1056/NEJMoa2405457) showed that CRISPR-mediated knockout of mutant TTR achieved meaningful reductions in serum TTR levels (up to 88% knockdown in some patients) and improved neuropathy scores over 6-12 months. Critically, no off-target editing or serious adverse events directly attributable to CRISPR were observed.
This is the proof-of-concept that in vivo gene editing can work with acceptable safety margins. The bar is now set: can you deliver CRISPR systemically and hit your target without collateral damage?
The limitations: NTLA-2001 achieves partial knockdown, not complete cure. Patients will likely need repeat dosing. Long-term durability data are still pending. Off-target effects may take years to manifest.
The Off-Target Editing Problem (And Why It’s Not a Deal-Breaker)
Every discussion of CRISPR safety returns to off-target editing: unintended cuts elsewhere in the genome. Early concerns were valid. Early SpCas9 designs had hundreds of off-target sites per cell.
Current evidence suggests the problem is smaller than feared but not solved. Anzalone et al. (2020) in Nature Biotechnology demonstrated that high-fidelity Cas9 variants reduce off-target activity by orders of magnitude (https://doi.org/10.1038/s41587-020-0453-z). Casgevy uses engineered nucleases designed for specificity.
For NTLA-2001 in vivo work, one-time dosing means off-target cuts are fewer in absolute number. For ex vivo therapies like Casgevy, you’re editing a small, selected population of cells and can screen for edits before infusion.
The honest assessment: off-target editing is real, but engineered nucleases, careful design, and cell selection mitigate it. The risk is low relative to the benefit for patients facing otherwise fatal or severely debilitating disease.
What’s in the Pipeline
Beyond Casgevy and NTLA-2001, several clinical trials are underway or opening in early 2026:
- CRISPR Therapeutics and Vertex are dosing patients with CTX001, an off-the-shelf edited T cell therapy for severe combined immunodeficiency (SCID). Unlike Casgevy’s patient-specific approach, CTX001 is allogeneic (uses donor cells). Clinical data should mature later in 2026.
- Editas Medicine (NTLA-2002 for Leber congenital amaurosis type 10) is preparing for Phase 2 expansion in retinal dystrophy. If approved, this would be an in vivo edit of photoreceptors, a major milestone.
- Base editing (cytosine and adenine editors, not traditional Cas9 nucleases) are entering early clinical trials. These tools make single-nucleotide changes without double-strand breaks, potentially safer for some applications.
What This Means for You
If you’re a molecular biologist: CRISPR therapeutic development is accelerating rapidly. Ex vivo therapies are moving into manufacturing and real-world deployment. If you work in gene therapy, pharma, or biotech, now is the time to deepen expertise in manufacturing scale-up, off-target assessment, and long-term safety monitoring.
If you’re a clinical researcher: CRISPR patient cohorts are growing. The data are preliminary, but phenotypic characterization of treated patients (neuropathy scores, imaging, quality of life) is critical. If you see CRISPR-treated patients, meticulous documentation will shape the field’s understanding of long-term outcomes.
If you’re an academic researcher: Therapeutic CRISPR is no longer a future promise. Funding agencies, journals, and collaborators are laser-focused on clinical translation. If your lab works on CRISPR (delivery, specificity, off-target mitigation, or novel nucleases), you’re in the right place at the right time.
If you’re training in gene therapy or biotechnology: This is a major inflection point in your field. The next 3-5 years will define which CRISPR approaches survive and scale. Understanding both the science and the business (manufacturing, regulatory, patient selection) will be essential.
The Honest Verdict
CRISPR works. Casgevy demonstrates that edited cells can function therapeutically in humans for years. NTLA-2001 shows that in vivo editing is feasible with reasonable safety. But CRISPR is not a universal fix. Early applications are narrow: monogenic diseases, hematologic malignancies, organ-specific targets (liver, eye).
The broader dream of correcting any genetic mutation anywhere in the body remains years away. Manufacturing remains expensive and slow. Off-target editing is manageable but not eliminated. Patient selection and long-term monitoring are essential.
What’s clear: we’ve moved past the lab. CRISPR is now a clinical reality. The field’s challenge is scaling it safely and broadly.
Stay tuned. 2026 will bring more Phase 2 data, manufacturing progress, and probably the first hints of which CRISPR approaches will dominate the 2030s.